CSL787

Phase 2Biologic

CSL Behring

CSL787 is one of 33 biologic programs targeting Cystic Fibrosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cystic FibrosisActive, not recruiting

Cystic FibrosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

Onglyza

AstraZeneca

Preclinical

2 2

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

3 3

Proair HFA

GGlaxo Dba Glaxosmithkline

Preclinical

2 4

Actimmune

HHorizon Therapeutics Ireland DAC

Preclinical

2 5

Aztreonam Lysine

Gilead

Preclinical

5 6

Advil

KKenvue Brands

Preclinical

1 7

Capromorelin

UUniversity of Aarhus

Preclinical

1 8

Amitiza

SSucampo Pharma Americas, LLC

Preclinical

1 9

Tums

Otsuka

Preclinical

1 10

Feosol

AAuerbach Hematology Oncology Associates P C

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Cystic Fibrosis

NCT07048262

Clinical

Trials by Indication[1]

Cystic Fibrosis2 trials

Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB)

Completed· CSL Behring logo

CSL Behring·Phase 1·NCT04643587·64 enrolled

Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)

Recruiting· CSL Behring logo

CSL Behring·Phase 2·NCT07048262·450 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CSL787. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CSL787 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CSL787. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSL Behring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: CSL Behring

CSL787

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Cystic Fibrosis2 trials

References

Drug Info

Quick Facts

Related News